Global strategic partner in healthcare, Avalere Health, is proud to announce the appointment of Amar Urhekar as its new Chief ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Almac Clinical Technologies is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering trial sponsors to pro-actively manage ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...